Metabolism

Stanford Study Identifies BRP as AI-Found Appetite Suppressant

Early animal tests show the natural peptide reduced food intake up to 50 percent while targeting the hypothalamus directly.

Published November 04, 2026 Read 2 min 361 words Topic Metabolism
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Identification of the BRP Peptide in Animal Models

Researchers at Stanford Medicine used artificial intelligence (AI) to identify a natural peptide called BRP that reduced food intake by up to 50 percent in animal trials.

The experiments showed that the compound stimulated fat loss alongside the reduction in feeding. Senior author Katrin Svensson, PhD, and lead author Laetitia Coassolo, PhD, published the findings in the journal Nature.

The animal data represents an initial laboratory discovery. Scientists are now preparing to evaluate whether the molecule is safe and functional in human subjects.

Differences Between BRP and Existing GLP-1 Medications

BRP acts selectively on populations of cells inside the hypothalamus rather than binding to receptors throughout the digestive tract and pancreas.

Standard obesity medications like semaglutide imitate glucagon-like peptide 1 (GLP-1), an appetite hormone. Because GLP-1 receptors exist in the gut and other organs, these drugs frequently cause digestive issues such as nausea, constipation, or delayed stomach emptying.

In contrast, Svensson noted that BRP concentrates its action in the hypothalamus. This selective focus may help individuals reduce food intake without experiencing common gastrointestinal symptoms or significant muscle loss.

Computational Screening of Natural Peptide Hormones

Computational screening allowed the research team to evaluate thousands of biological compounds to locate functional fragments cut from inactive prohormones.

Human cells produce thousands of small protein fragments during normal metabolic processes. Specialized enzymes cut larger prohormone proteins into peptides, but only a small portion act as active signaling messengers for appetite and energy regulation.

Separating valuable hormones from inactive peptide debris has historically been difficult. The machine-learning screen flagged BRP out of thousands of candidates, allowing researchers to isolate and synthesize it for laboratory validation.

Current Study Limitations and Next Steps

The reported findings come entirely from animal models and have not been confirmed in clinical human testing.

Rodent appetite pathways do not always mirror human metabolic responses. Because of this gap, the compound cannot yet be considered safe, tolerable, or effective for human weight management.

Svensson cofounded a biotechnology company to advance BRP toward Phase 1 clinical trials. Those future trials must determine tolerable dosage ranges, compound stability, and potential adverse effects before any therapeutic application exists.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want medical weight loss instead of another diet?

Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.

See Opt Health's weight-loss program →

Topic updates

Get the weekly metabolic health roundup

Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results